High Content Screening Companies

The global high content screening market is anticipated to reach USD 2.19 billion in 2030 from USD 1.52 billion in 2025, with a significant CAGR of 7.5%. The high content screening market is competitive, with key players strategizing to capture the majority of market share. Prominent players in the high content screening market are Danaher Corporation (US), Revvity, Inc. (US), BD (US), Carl Zeiss AG (Germany), and Thermo Fisher Scientific Inc. (US), among others. The key market players adopt various growth strategies, such as organic and inorganic, that include partnerships, agreements, expansions, and acquisitions, to strengthen their position in the high content screening market.

Danaher (US) is one of the leading players in the high content screening market. The company has a presence in more than 60 countries and offers a diversified product portfolio of instruments and software in the high content screening market. Danaher strongly focuses on organic and inorganic growth strategies to maintain a dominant position in the market. The company operates in the market through Beckman Coulter, Molecular Devices, and Integrated DNA Technologies, among others. Danaher’s robust global distribution network and dedicated customer support help the company to maintain its dominant position in the market.

To know about the assumptions considered for the study download the pdf brochure

Revvity, Inc. (US) is one of the dominant players in the high content screening market. The company has a global presence in more than 150 countries and has diversified products for the high content screening market. The company’s product offerings include instruments, software, and consumables such as automated cell counter, flow cytometer, microscope, cell imaging systems, and microplate readers. A robust global distribution network and customer-centric approach ensure Revvity serves diverse sectors, including academia, biotechnology, and pharmaceuticals.

Market Ranking

The high content screening (HCS) market is highly competitive, with five main players collectively holding 44-48% of the total market share. Danaher offers a diversified product portfolio of instruments and software in the high content screening market. The Revvity has a significant market presence through its focus on cell counting and analysis systems and consumables. BD has solidified their positions by offering automated cellular imaging for phenotypic screening and high-throughput, multi-parameter cellular analysis. As demand for high content screening rises, current vendors are enhancing their HCS solutions to meet the evolving need for drug discovery & development.

The remaining 52-56% of the market is shared among other regional and emerging vendors, contributing to extensive fragmentation and offering opportunities for smaller players to establish a footprint. Market competition is driven by several key factors, including technological advancements, product innovation, strategic collaborations, and increasing demand from pharmaceutical and biotechnology companies.

Related Reports:

High Content Screening Market by Product & Services (Instrument (Cell Imaging, Analysis System), Consumables (Reagents & Assay Kits, Microplates), Software), Application (Drug Discovery & Development, Toxicology), End User - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com